Bravehaeart Bio IPO

Develops precision heart-disease therapies for patients with unmet cardiovascular needs.

NASDAQ: BRVE

Buy

Buy Private Stock

Sign up to invest in private companies like Bravehaeart Bio before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Bravehaeart Bio before their IPO.

Overview

Bravehaeart Bio completed their IPO on August 6, 2026. Now that Bravehaeart Bio is a public company, Nasdaq Private Market does not actively track its performance. The data below is for reference before the company’s IPO.

Braveheart Bio is a clinical-stage biotechnology company that develops precision small-molecule therapies targeting cardiovascular disease. It focuses on advancing a proprietary inhibitor designed to improve heart muscle function and treat hypertrophic cardiomyopathy with a novel mechanism. The company’s core mission is to pioneer next-generation treatments that address underlying heart conditions rather than only symptoms.

Sector

Healthcare & Life Sciences

Founded

2024

Headquarters

San Francisco, CA

Bravehaeart Bio Funding

Bravehaeart Bio Funding History Pre-IPO

Gain insights into Bravehaeart Bio funding history prior to their IPO, including the funding round, time period, and amount raised.

Financing Round Date Amount Price per share Valuation
Round Date Amount PPS Valuation
Series A Nov 05, 2025 185M
XXXXX
XXXXX

Access the PPS, Valuation details, and a wealth of other data by signing up. Source: Nasdaq Private Market

Buy

Buy Private Stock

Sign up to invest in private companies like Bravehaeart Bio before their IPO.

Sell

Sell Private Stock

Sign up to sell private companies like Bravehaeart Bio before their IPO.

Bravehaeart Bio Management Team

Bravehaeart Bio people and management – Prior to IPO

  • CFO
    Paul Rickey
  • Chief Development Officer
    Michele Anderson
  • President, CEO
    Travis Murdoch

Investors

Major Bravehaeart Bio investors

  • Enavate Sciences

  • Andreessen Horowitz

  • OrbiMed Advisors

  • Forbion Capital Partners

  • Frazier Life Sciences Management

Bravehaeart Bio Valuations & Financials

Looking for private company valuations and share price data?

Nasdaq Private Market Data & Intelligence is the private company valuation database covering 4,000+ venture-backed companies with daily pricing, financing history, and secondary market activity. View real-time NPM data on pre-IPO companies including valuations, private company comparable transactions, and historical share price information — the private company due diligence data sources institutional investors rely on.

Similar Companies

Explore companies

like Bravehaeart Bio

  • Cerebral

    Healthcare & Life Sciences

    Telemedicine mental health startup, providing evidence-based therapeutic techniques and medication management.

  • Devoted Health

    Healthcare & Life Sciences

    Provides Medicare Advantage plans to improve older Americans' well-being with comprehensive and family-oriented care.

  • Roman Health Ventures-Logo

    Ro

    Healthcare & Life Sciences

    Healthcare technology for a patient-centric healthcare system.

  • Virta Health-Logo

    Virta Health

    Healthcare & Life Sciences

    Online specialty medical clinic focused on reversing type 2 diabetes.

  • Somatus-Logo

    Somatus

    Healthcare & Life Sciences

    Integrated care for patients with or at risk of developing kidney disease.

  • Color-Logo

    Color

    Healthcare & Life Sciences

    Physician-ordered genetic testing with comprehensive support, utilizing advanced software and a certified laboratory.

  • Insitro-Logo

    insitro

    Healthcare & Life Sciences

    Drug discovery and development company.

  • Cedar Inc-Logo

    Cedar

    Healthcare & Life Sciences

    The tech platform uses modern intelligence to improve healthcare financial experiences for everyone.

  • Eikon Therapeutics Inc-Logo

    Eikon Therapeutics

    Healthcare & Life Sciences

    Uses revolutionary technology to discover novel treatments for life-threatening diseases.

FAQ

Questions?

We have answers

Buy Bravehaeart Bio Stock

Bravehaeart Bio became publicly traded following its IPO on August 6, 2026, its shares now trade on public stock exchanges under the ticker symbol NASDAQ: BRVE. Before the IPO, Bravehaeart Bio stock was privately held and available only through private market transactions.

If you’re an accredited investor looking to purchase pre-IPO shares in a private company, Nasdaq Private Market can help you get started. Learn more about investing in the private market or sign up for free to explore available opportunities. Learn more about how private company shares trade prior to an IPO on our investors page.

Sell Bravehaeart Bio Stock

Following its IPO on August 6, 2026, Bravehaeart Bio shares trade on public stock exchanges, allowing shareholders to sell stock through a traditional brokerage.

If you currently hold shares in a private company, Nasdaq Private Market may be able to help you explore your sell private company stock. Our platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To understand how employees sell shares before a company goes public, visit the Employee Shareholders page.

 

Bravehaeart Bio Stock Price

Following the IPO, Bravehaeart Bio stock prices can now be viewed publicly on major exchanges. Investors and interested parties can find the current stock price by searching Bravehaeart Bio’s ticker symbol on financial platforms such as Nasdaq.com or through their preferred brokerage platform.

Bravehaeart Bio Stock Ticker Symbol

Following its IPO on August 6, 2026, Bravehaeart Bio stock now trades on public markets under the ticker symbol NASDAQ: BRVE. You can view real-time stock information through widely used financial data platforms.

Criteria to Sell Bravehaeart Bio Stock

Following the Bravehaeart Bio IPO, public shares can be sold through any brokerage.

Nasdaq Private Market works with employees, ex-employees, and other private company shareholders of pre-IPO companies to sell their shares. The Nasdaq Private Market platform provides a secure and compliant way to sell your shares on terms that work for both you and the company. To learn more about how to sell private company stock, visit the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

 

Criteria to Buy or Invest in Bravehaeart Bio Stock

Following Bravehaeart Bio’s initial public offering on August 6, 2026, its shares are now listed on a public exchange and available for purchase through a brokerage account. Investors interested in buying Bravehaeart Bio stock can do so through their preferred broker, just as they would with any other publicly traded security.

Nasdaq Private Market continues to work with investors seeking exposure to private company opportunities prior to IPO. Through structured transactions and curated offerings, investors can participate in private market activity before companies enter the public markets.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

Bravehaeart Bio Stock Settlement

Since Bravehaeart Bio is now publicly traded, public-market share transfers and settlement occur automatically through a brokerage or exchange.

Nasdaq Private Market supports transfer and settlement for privately held company equity. In order to buy or sell private company stock, share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patented Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

Bravehaeart Bio IPO

Bravehaeart Bio completed its IPO on August 6, 2026, and is now publicly available through major financial sources.